214 related articles for article (PubMed ID: 12727643)
1. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice.
Foell J; McCausland M; Burch J; Corriazzi N; Yan XJ; Suwyn C; O'Neil SP; Hoffmann MK; Mittler RS
Ann N Y Acad Sci; 2003 Apr; 987():230-5. PubMed ID: 12727643
[TBL] [Abstract][Full Text] [Related]
2. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.
Foell J; Strahotin S; O'Neil SP; McCausland MM; Suwyn C; Haber M; Chander PN; Bapat AS; Yan XJ; Chiorazzi N; Hoffmann MK; Mittler RS
J Clin Invest; 2003 May; 111(10):1505-18. PubMed ID: 12750400
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy with agonistic anti-CD137: two sides of a coin.
Sun Y; Chen JH; Fu Y
Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
[TBL] [Abstract][Full Text] [Related]
5. Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling.
Sun Y; Blink SE; Chen JH; Fu YX
J Immunol; 2005 Jul; 175(2):884-90. PubMed ID: 16002686
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells.
Shao H; Fu Y; Liao T; Peng Y; Chen L; Kaplan HJ; Sun D
Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):596-603. PubMed ID: 15671287
[TBL] [Abstract][Full Text] [Related]
7. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.
Foell JL; Diez-Mendiondo BI; Diez OH; Holzer U; Ruck P; Bapat AS; Hoffmann MK; Mittler RS; Dannecker GE
Immunology; 2004 Sep; 113(1):89-98. PubMed ID: 15312139
[TBL] [Abstract][Full Text] [Related]
8. Stimulation with 4-1BB (CD137) inhibits chronic graft-versus-host disease by inducing activation-induced cell death of donor CD4+ T cells.
Kim J; Choi WS; La S; Suh JH; Kim BS; Cho HR; Kwon BS; Kwon B
Blood; 2005 Mar; 105(5):2206-13. PubMed ID: 15522958
[TBL] [Abstract][Full Text] [Related]
9. 4-1BB (CD137) differentially regulates murine in vivo protein- and polysaccharide-specific immunoglobulin isotype responses to Streptococcus pneumoniae.
Wu ZQ; Khan AQ; Shen Y; Wolcott KM; Dawicki W; Watts TH; Mittler RS; Snapper CM
Infect Immun; 2003 Jan; 71(1):196-204. PubMed ID: 12496166
[TBL] [Abstract][Full Text] [Related]
10. Activation of c-jun N-terminal kinase by 4-1BB (CD137), a T cell co-stimulatory molecule.
Kim HH; Kwack K; Lee ZH
Mol Cells; 2000 Jun; 10(3):247-52. PubMed ID: 10901161
[TBL] [Abstract][Full Text] [Related]
11. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
12. The Progress of Investigating the CD137-CD137L Axis as a Potential Target for Systemic Lupus Erythematosus.
Mak A; Schwarz H
Cells; 2019 Sep; 8(9):. PubMed ID: 31500130
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Th2-mediated allergic airway inflammatory disease by CD137 costimulation.
Sun Y; Blink SE; Liu W; Lee Y; Chen B; Solway J; Weinstock J; Chen L; Fu YX
J Immunol; 2006 Jul; 177(2):814-21. PubMed ID: 16818735
[TBL] [Abstract][Full Text] [Related]
14. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.
Zhang H; Knutson KL; Hellstrom KE; Disis ML; Hellstrom I
Mol Cancer Ther; 2006 Jan; 5(1):149-55. PubMed ID: 16432173
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice.
Sabel MS; Conway TF; Chen FA; Bankert RB
J Immunother; 2000; 23(3):362-8. PubMed ID: 10838665
[TBL] [Abstract][Full Text] [Related]
16. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
17. CD137-mediated immunotherapy for allergic asthma.
Polte T; Foell J; Werner C; Hoymann HG; Braun A; Burdach S; Mittler RS; Hansen G
J Clin Invest; 2006 Apr; 116(4):1025-36. PubMed ID: 16528411
[TBL] [Abstract][Full Text] [Related]
18. Role of 4-1BB in immune responses.
Vinay DS; Kwon BS
Semin Immunol; 1998 Dec; 10(6):481-9. PubMed ID: 9826581
[TBL] [Abstract][Full Text] [Related]
19. Preferential blockade of CD8(+) T cell responses by administration of anti-CD137 ligand monoclonal antibody results in differential effect on development of murine acute and chronic graft-versus-host diseases.
Nozawa K; Ohata J; Sakurai J; Hashimoto H; Miyajima H; Yagita H; Okumura K; Azuma M
J Immunol; 2001 Nov; 167(9):4981-6. PubMed ID: 11673505
[TBL] [Abstract][Full Text] [Related]
20. 4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.
Lee J; Lee EN; Kim EY; Lee HJ; Park HJ; Sun CL; Lee SK; Joh JW; Lee KW; Kwon GY; Kim SJ
Transplant Proc; 2005; 37(1):123-5. PubMed ID: 15808569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
